December 2010
Volume 51, Issue 12
Free
Letters to the Editor  |   December 2010
The Effect of Bevacizumab on Human Tenon Fibroblasts in Ocular Wound Healing
Author Affiliations & Notes
  • Tine Van Bergen
    Laboratory of Ophthalmology, Katholieke Universiteit, Leuven, Belgium; and
  • Ingeborg Stalmans
    Laboratory of Ophthalmology, Katholieke Universiteit, Leuven, Belgium; and
    Ophthalmology Department, University Hospitals, Leuven, Belgium.
Investigative Ophthalmology & Visual Science December 2010, Vol.51, 6903-6904. doi:10.1167/iovs.10-6116
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Tine Van Bergen, Ingeborg Stalmans; The Effect of Bevacizumab on Human Tenon Fibroblasts in Ocular Wound Healing. Invest. Ophthalmol. Vis. Sci. 2010;51(12):6903-6904. doi: 10.1167/iovs.10-6116.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
We have read the paper “Antifibrotic Activity of Bevacizumab of Human Tenon's Fibroblasts In Vitro” of O'Neill et al. 1 (published in Recently Accepted Papers on June 23, 2010) with great interest. We would like to thank the authors for their interesting work and for referring to our paper. 2  
Unfortunately, our work has been erroneously cited with regard to the following points: 
In the discussion of their paper (page 13, 2nd paragraph) the authors mention:
 

Li et al.39 found a single dose of 0.75 mg bevacizumab (0.03 mL of 25 mg/mL) given immediately after surgery significantly reduced the density of blood vessels and the number of inflammatory cells during the early stages of wound healing and reduced the collagen deposition in the later stages.

  1.  
    We injected a total volume of 300 μL (0.3 mL) instead of 0.03 mL; therefore, the dose and volume should be changed to: “… a single dose of 7.5 mg bevacizumab (0.3 mL of 25 mg/mL)… .”
  2.  
    We never observed (or reported) an effect of inflammation after a single injection of bevacizumab; therefore, the phrase “… and the number of inflammatory cells…” should be removed.
Therefore, we feel that this statement should be changed as follows:
 

Li et al.39 found that a single dose of 7.5 mg bevacizumab (0.3 mL of 25 mg/mL) given immediately after surgery significantly reduced the density of blood vessels during the early stages of wound healing and reduced the collagen deposition in the later stages.

 
Once again, we are delighted that the authors cited our work, but we would greatly appreciate having these corrections conveyed to the readers. 
References
O'Neill EC Qin Q Van Bergen NJ . Antifibrotic activity of bevacizumab on human Tenon's fibroblasts in vitro. Invest Ophthalmol Vis Sci. 2010;51:6524–6532. [CrossRef] [PubMed]
Li Z Van Bergen T Van de Veire S . Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery. Invest Ophthalmol Vis Sci. 2009;50:5217–5225. [CrossRef] [PubMed]
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×